EFFICACY AND SAFETY OF GEMCITABINE AS FIRST-LINE THERAPY IN PATIENTS AGED 65 AND OLDER WITH ADVANCED PANCREATIC CANCER

被引：0
|
作者：
Kito, Yosuke [1 ]
Todaka, Akiko [1 ]
Fukutomi, Akira [1 ]
Kunieda, Kenji [1 ]
Tsushima, Takahiro [1 ]
Yokota, Tomoya [1 ]
Machida, Nozomu [1 ]
Yamazaki, Kentaro [1 ]
Onozawa, Yusuke [2 ]
Yasui, Hirofumi [1 ]
机构：
[1] Shizuoka Canc Ctr, Divisiont Gastrointestinal Oncol, Shizuoka, Japan
[2] Shizuoka Canc Ctr, Div Med Oncol, Shizuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu435.120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O3-13-3
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer
    Liu, Haonan
    Pan, Di
    Yao, Zhiyuan
    Wang, Hongmei
    Li, Yuqi
    Qin, Xiaobing
    Qu, Pengfei
    Tang, Juanjuan
    Han, Zhengxiang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 139
  • [22] Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
    Cartwright, Thomas H.
    Ginsburg, Aimee
    Wilfong, Lalan S.
    Harrell, Robyn K.
    Hoverman, J. Russell
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
    Arlen, Aimee Ginsburg
    Cartwright, Thomas H.
    Wilfong, Lalan S.
    Hoverman, J. Russell
    Nelson, Greg C.
    Turnwald, Brian
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer
    Yip, D
    Goldstein, D
    CANCER TREATMENT REVIEWS, 2005, 31 (03) : 236 - 241
  • [25] Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Stefanou, Dimitra
    Magou, Elpida
    Zylis, Dimosthenis
    Kapiris, Matthaios
    Nasi, Despoina
    Georganta, Chara
    Ardavanis, Alexandros
    IN VIVO, 2018, 32 (03): : 653 - 657
  • [26] Updated use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine
    Cartwright, Thomas H.
    Arlen, Aimee Ginsburg
    Wilfong, Lalan S.
    Harrell, Robyn K.
    Hoverman, J. Russell
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer
    Vaccaro, Vanja
    Bria, Emilio
    Sperduti, Isabella
    Gelibter, Alain
    Moscetti, Luca
    Mansueto, Giovanni
    Ruggeri, Enzo Maria
    Gamucci, Teresa
    Cognetti, Francesco
    Milella, Michele
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (28) : 4511 - 4519
  • [28] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer
    Vanja Vaccaro
    Emilio Bria
    Isabella Sperduti
    Alain Gelibter
    Luca Moscetti
    Giovanni Mansueto
    Enzo Maria Ruggeri
    Teresa Gamucci
    Francesco Cognetti
    Michele Milella
    World Journal of Gastroenterology, 2013, (28) : 4511 - 4519
  • [29] Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma
    Trestini, Ilaria
    Carbognin, Luisa
    Peretti, Umberto
    Sperduti, Isabella
    Caldart, Alberto
    Tregnago, Daniela
    Avancini, Alice
    Auriemma, Alessandra
    Orsi, Giulia
    Pilotto, Sara
    Frulloni, Luca
    Capurso, Gabriele
    Bria, Emilio
    Reni, Michele
    Tortora, Giampaolo
    Milella, Michele
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] First-Line Treatment for Advanced Pancreatic Cancer
    Oberstein, Paul E.
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2011, 12 (02): : 96 - 100
12345